Login to Your Account

ARCUS covenant: Precision Bioscience enters $1.6B deal with Baxalta, 'Jones'-ing for CAR T

By Randy Osborne
Staff Writer

Thursday, February 25, 2016

So far, the data with allogeneic CAR T-cell therapies say, "liquid tumors yes, solid tumors not yet," Precision Bioscience Inc.'s Chief Scientific Officer Derek Jantz told BioWorld Today, but his genome-editing firm looks to make "significant improvements to the status quo."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription